Abstract #4240

Comparison of gadoterate meglumine and gadobutrol in MRI diagnosis of brain tumors: a double-blind randomized intra-individually controlled in cross-over study (the REMIND study)

Kenneth Maravilla¹, Daniel San Juan Orta², Sang Joon Kim³, and Guillermo Elizondo Riojas⁴

¹Radiology, University of Washington, Seattle, WA, United States, ²Clinical Research Institute S.C., Tlanepantla de Baz, Mexico, ³Asan medical center / Radiology, Seoul, Korea, Democratic People's Republic of, ⁴Universidad Autonoma de Nuevo Leon, Hospital Universitario Dr. Jose Eleuterio Gonzalez, Monterrey, Mexico

This double-blind randomized cross-over study was conducted to demonstrate non-inferiority of gadoterate meglumine vs. gadobutrol in MRI diagnosis of brain tumors. Images from two identical MRIs with each agent were evaluated by three independent off-site readers. Overall lesion visualization and characterization was scored as “good” or “excellent” in >90% of patients by all readers. Despite a small difference in signal intensity measurements in favor of gadobutrol, similar results were observed with the two agents regarding overall lesion visualization and characterization or qualitative efficacy criteria. Non-inferiority of gadoterate meglumine vs. gadobutrol in diagnosis of brain tumors by MRI was demonstrated.

This abstract and the presentation materials are available to members only; a login is required.

Join Here